<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577056</url>
  </required_header>
  <id_info>
    <org_study_id>1028883</org_study_id>
    <secondary_id>NHMRC1028883</secondary_id>
    <nct_id>NCT01577056</nct_id>
  </id_info>
  <brief_title>Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils</brief_title>
  <acronym>FIFH</acronym>
  <official_title>Effect of Fish Oil Supplementation on Postprandial Lipid Metabolism in Familial Hypercholesterolaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Western Australia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fish oil supplementation is effective in
      the treatment of abnormal fat metabolism in subjects with elevated cholesterolaemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of statin therapy in familial hypercholesterolaemia (FH) is known to reduce
      cardiovascular risk and is a first line recommendation, however, there is considerable
      residual risk predicted by the presence of fasting and post-prandial hypertriglyceridaemia.

      This study will examine the effect of oral n-3 fatty acid ethyl esters supplementation
      (4g/day, Omacor) on postprandial hypertriglyceridaemia and post-prandial arterial function
      when administrated to FH patients at increased risk of cardiovascular disease due to their
      residual fasting hypertriglyceridaemia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial changes in triglyceride-rich lipoprotein concentrations</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incremental area-under-the-curve (AUC) for triglycerides, apoB-48 and retinyl palmitate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglyceride-rich lipoprotein kinetics</measure>
    <time_frame>12 weeks</time_frame>
    <description>Kinetic studies of apoB48 and apoB-100 kinetics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertriglyceridaemia</condition>
  <condition>Familial Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>FH subjects with standard treatment (statin treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil capsule</intervention_name>
    <description>4g Omega capsule for 12 weeks</description>
    <arm_group_label>Fish oil</arm_group_label>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMG Coenzyme reductase</intervention_name>
    <description>All FH subjects are on standard statin treatment during study period</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with FH (genetically defined LDL-receptor mutation or Dutch score &gt;8) on
             statin treatment only

          -  Hypertriglyceridaemia on a random blood sample (triglycerides &gt;1.5mml/L)

        Exclusion Criteria:

          -  Subjects with diabetes mellitus

          -  major systemic illness or use of steroids or other lipid-regulating drugs (such as
             niacin, fibrate and colesevelam)

          -  patients on hypocaloric diets or LDL apheresis; anaemia, haemorrhage and pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dick Chan, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Western Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dick Chan, PhD</last_name>
    <phone>61-8-92240268</phone>
    <email>dick.chan@uwa.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Medicine &amp; Pharmacology,University of Western Australia</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dick Chan, PhD</last_name>
      <phone>61-8-92240268</phone>
      <email>dick.chan@uwa.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>April 11, 2012</last_update_submitted>
  <last_update_submitted_qc>April 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Western Australia</investigator_affiliation>
    <investigator_full_name>Dick C Chan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Familial hypercholesterolaemia</keyword>
  <keyword>Postprandial dyslipidaemia</keyword>
  <keyword>Fish oil treatment</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

